A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

1100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2005-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

NCT00092404

Measles Mumps Rubella +1 more

COMPLETED PHASE2

Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

NCT00432523

Measles Mumps Varicella

COMPLETED PHASE3

Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

NCT02058563

Rubella Mumps Measles

COMPLETED PHASE3

Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial

NCT04394689

Measles Rubella Vaccination +1 more

COMPLETED PHASE1/PHASE2

ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)

NCT00975507

Measles Mumps Rubella +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The duration of treatment is 6 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Measles

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

V205C, measles, mumps, and rubella virus vaccine live

Intervention Type BIOLOGICAL

Comparator: Measles, Mumps, and Rubella Virus Vaccine Live

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy children 12 to 18 months of age.

Exclusion Criteria

* Previous receipt of measles, mumps, rubella and/or varicella vaccine.
* Prior infection or exposure to (within last 4 weeks) measles, mumps, rubella, varicella and/or zoster.
* Any medical condition that might interfere with the immune response to the given vaccines (including HIV infection and/or cancer) or has undergone immunosuppressive (weakens your body's ability to fight infection) therapy.
* History of seizures (convulsions)
* Allergies to any component of the vaccine, including sorbitol, gelatin, or neomycin.
* A recent (within the last 3 days) illness resulting in a fever (underarm temperature greater than 99.5° F \[37.5° C\]).

Minimum Eligible Age

12 Months

Maximum Eligible Age

18 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes